Postmortem Interval Influences α-Synuclein Expression in Parkinson Disease Brain
Table 2
Characteristics of the PD cases and controls included in analysis.
Site
Type
Gender
Age, years (range)
PMI, hours (range)
Tissue pH (range)
PD Duration, years (range)
HBSFRC
2 C
2M
86.5 (80–93)
19.5 (13–26)
6.41 (6.26–6.55)
N/A
17 PD
9F/8M
82.2 (63–95)
16.3 (9–37)
6.30 (6.02–6.62)
11.5 (4–28)
BTRC
39 C
39M
61.4 (36–106)
21.9 (10–39.6)
6.71 (5.95–7.32)
N/A
35 PD
35M
76.3 (64–95)
17.9 (6.6–30.7)
6.50 (5.86–7.13)
11.2 (3–23)
SHRI
23 C
13F/10M
84.3 (63–97)
2.68 (1–5.5)
6.71 (6.29–7.13)
N/A
49 PD
11F/38M
78.5 (64–90)
3.11 (1–10)
6.59 (6.17–7.44)
10.4 (0–40)
All
64 C
13F/51M
70.5 (36–106)
14.9 (1–39.6)
6.70 (5.95–7.32)
N/A
101 PD
20F/81M
78.3 (63–95)
10.4 (1–37)
6.51 (5.86–7.44)
10.9 (0–40)
Final C Set*
46 C
13F/33M
77.2 (58–97)
11.7 (1–39.6)
6.67 (5.95–7.32)
N/A
C: Control; PD: Parkinson disease. HBSFRC = Human Brain and Spinal Fluid Resource Center VA West Los Angeles Healthcare Center. HBTRC = Harvard Brain Tissue Resource Center, McLean Hospital, Belmont, Massachusetts. SHRI = Sun Health Research Institute in Sun City, Arizona.
*after removing controls with age at death ± 5 years beyond age at death of cases (< age 58 or > age 100).
